Abivax SA (ABVX)
84.99
-2.02
(-2.32%)
USD |
NASDAQ |
Oct 08, 11:47
Abivax Enterprise Value : 6.486B for Oct. 7, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 07, 2026 | 6.486B |
| October 06, 2026 | 6.583B |
| October 05, 2026 | 6.863B |
| October 02, 2026 | 6.955B |
| October 01, 2026 | 7.132B |
| September 30, 2026 | 7.445B |
| September 29, 2026 | 7.403B |
| September 28, 2026 | 7.272B |
| September 25, 2026 | 6.809B |
| September 24, 2026 | 7.114B |
| September 23, 2026 | 7.055B |
| September 22, 2026 | 7.387B |
| September 21, 2026 | 7.798B |
| September 18, 2026 | 7.925B |
| September 17, 2026 | 8.081B |
| September 16, 2026 | 7.701B |
| September 15, 2026 | 8.055B |
| September 14, 2026 | 8.607B |
| September 11, 2026 | 9.011B |
| September 10, 2026 | 8.796B |
| September 09, 2026 | 9.076B |
| September 08, 2026 | 9.036B |
| September 04, 2026 | 8.704B |
| September 03, 2026 | 8.643B |
| September 02, 2026 | 8.407B |
| Date | Value |
|---|---|
| September 01, 2026 | 8.614B |
| August 31, 2026 | 8.459B |
| August 28, 2026 | 8.589B |
| August 27, 2026 | 8.664B |
| August 26, 2026 | 8.842B |
| August 25, 2026 | 8.954B |
| August 24, 2026 | 8.812B |
| August 21, 2026 | 8.716B |
| August 20, 2026 | 8.975B |
| August 19, 2026 | 9.164B |
| August 18, 2026 | 9.035B |
| August 17, 2026 | 9.178B |
| August 14, 2026 | 9.036B |
| August 13, 2026 | 9.235B |
| August 12, 2026 | 9.560B |
| August 11, 2026 | 9.663B |
| August 10, 2026 | 9.718B |
| August 07, 2026 | 9.992B |
| August 06, 2026 | 9.918B |
| August 05, 2026 | 9.550B |
| August 04, 2026 | 9.534B |
| August 03, 2026 | 9.501B |
| July 31, 2026 | 9.512B |
| July 30, 2026 | 9.465B |
| July 29, 2026 | 9.027B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Poxel SA | -- |
| OSE Immunotherapeutics SA | -- |
| Cogent Biosciences, Inc. | 4.690B |
| Arrowhead Pharmaceuticals, Inc. | 8.452B |
| Oncolytics Biotech, Inc. | 70.59M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -136.54M |
| Total Expenses (Quarterly) | 136.54M |
| EPS Diluted (Quarterly) | -1.714 |
| Earnings Yield | -7.18% |
| Normalized Earnings Yield | -5.916 |